Pneumagen is developing glycan targeted carbohydrate binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer.
Latest news
Sep 10, 2019
Pneumagen Demonstrates Preclinical Proof-of-Concept for Neumifil™ in Respiratory Syncytial Virus Infections
Oct 15, 2019
Pneumagen Demonstrates Preclinical Proof-of-Concept in Oncology for Neumonco, a Novel Carbohydrate Binding Module
Mar 17, 2020
Pneumagen Ltd Leverages its Novel Glycan Approach to Target Coronavirus (COVID-19) Infections
Meet the team
Douglas Thomson
Chief Executive Officer
Dr Helen Connaris
Chief Scientific Officer
Professor Garry Taylor
Director and Chairman of Scientific Advisory Board
Thomas Engelen
Non-executive Chairman